IRRAS Announces CE Mark Approval for its Enhanced IRRAflow Dual-Lumen Catheter

Stockholm, October 7, 2021 – IRRAS, a commercial-stage medical technology company with a comprehensive portfolio of innovative products for neurocritical care, today announced the approval for an enhanced IRRAflow dual-lumen catheter in Europe. DEKRA, the company’s notified body, recently approved upgrades to the catheter, which is placed in the intracranial space as part of the IRRAflow system to perform active fluid exchange. This enhanced catheter is already being used commercially in the United States.

IRRAflow, the company’s initial commercial product, is a transformative medical device that offers intracranial fluid exchange by combining controlled irrigation and ongoing fluid drainage to better manage neurocritical care patients. The new IRRAflow 2.0 catheter now incorporates improved kink resistance, which improves catheter deliverability, and an upgraded dual-lumen design that results in optimized irrigation and drainage rates.

“We are pleased to receive CE Mark approval for our enhanced IRRAflow catheter in Europe,” said, Will Martin, President and Chief Executive Officer of IRRAS. “We have received positive feedback from the early clinical experience with this new catheter in the US, and we are excited to offer our growing list of European customers the latest IRRAflow innovations.”

About IRRAS

IRRAS is a global medical care company focused on delivering innovative medical solutions to improve the lives of critically ill patients. IRRAS designs, develops, and commercializes neurocritical care products that transform patient outcomes and decrease the overall cost of care by addressing complications associated with current treatment methodologies. IRRAS markets and sells its comprehensive, innovative IRRAflow and Hummingbird ICP Monitoring product lines to hospitals worldwide through its direct sales organization in the United States and select European countries as well as an international network of distribution partners.  

IRRAS maintains its headquarters in Stockholm, Sweden, with corporate offices in Munich, Germany, and San Diego, California, USA. For more information, please visit www.irras.com. 

IRRAS is listed on Nasdaq Stockholm (ticker: IRRAS). 

For more information, please contact: 

USA
Will Martin
President and CEO

ir@irras.com 

Europe
Sten Gustafsson
Director, Investor Relations
sten.gustafsson@irras.com
+46 102 11 5172 

The information was released for public disclosure, through the agency of the contact person above, on October 7, 2021 at 08:30 (CET). 

IRRAS’ IRRAflow[®] System Demonstrates Ability to Treat Pyogenic Ventriculitis through Targeted Delivery of Antibiotics in Case Series Published in Neurosurgery Open

Stockholm, September 29, 2021 – IRRAS, a global medical technology company with a comprehensive portfolio of innovative products for neurocritical care, today announced the publication of a case series in the Neurosurgery Open medical journal that demonstrates the ability of its IRRAflow system to treat aggressive brain infections by delivering needed antibiotics directly to the infection site.  The published patient treatments were performed by Dr. Behnam Rezai Jahromi at Helsinki University Hospital (HUH), one of the world’s leading hospitals for neurosurgical treatment.

The case series documents the survival of two patients that were diagnosed with pyogenic ventriculitis, a rare and debilitating infection of the lining of the ventricles in the brain that store cerebrospinal fluid (CSF).  Patients suffering from such infections face mortality and long-term disability rates of 60% and 80%, respectively.  Typically, ventriculitis is treated with long-term treatment of IV antibiotics, but the blood-brain barrier (BBB) makes it difficult for such drugs to reach therapeutic levels in the brain.

In the case series, Dr. Rezai Jahromi concluded that, with IRRAflow treatment, “the drainage of purulent fluid caused by healthcare associated ventriculitis or meningitis is now possible without harming brain tissue and intracranial pressure (ICP), while also changing the composition of CSF to an antibiotic-consisted fluid.”

This published case series is the first deliverable from the previously announced long-term collaboration between IRRAS and the neurosurgery team from Helsinki University.  HUH Neurosurgery is world-famous for its expertise in all subsections of neurosurgery and is considered one of the leading centers in Europe in the microneurosurgical treatment of cerebral blood vessel diseases and complex brain tumors.  Each year, more than 3,200 patients undergo neurosurgical treatment at Helsinki, and nearly 200 neurosurgeons from all around the world visit the facility to learn the latest techniques in neurosurgery.  

“Previously, leading neurosurgeons published their successful experience of delivering drugs that reduce spasm or prevent blood clot formation using IRRAflow’s irrigation,” said Will Martin, President and Chief Executive Officer.  “This case series is the first time that IRRAflow’s ability to irrigate with antibiotics has been documented in scientific literature, and it further validates the versatility of IRRAflow in treating a wide range of intracranial pathologies.  These critically ill patients have historically experienced extremely poor life expectancy, and we are pleased that IRRAflow may provide an option to improve their prognosis.”

With this case series now published, IRRAS’ partnership with HUH will now focus upon the ability to treat patients with intraventricular hemorrhage (IVH) with IRRAflow by irrigating thrombolytic medication to enhance clot removal.  Dr. Rezai Jahromi will present his IVH treatment experience with IRRAflow in a poster presentation at the upcoming Congress of Neurosurgical Surgeons (CNS) annual meeting in Austin, TX, from October 16 -20, 2021, and he will also serve as the Primary Investigator (PI) in the upcoming ARCH clinical study that will study IVH treatment using IRRAflow to irrigate thrombolytic medication.

A link to the publication, “Active Cerebrospinal Fluid Exchange System for Treatment of Pyogenic Ventriculitis,” can be found here: https://doi.org/10.1093/neuopn/okab030.

About IRRAS

IRRAS is a global medical care company focused on delivering innovative medical solutions to improve the lives of critically ill patients. IRRAS designs, develops, and commercializes neurocritical care products that transform patient outcomes and decrease the overall cost of care by addressing complications associated with current treatment methodologies. IRRAS markets and sells its comprehensive, innovative IRRAflow and Hummingbird ICP Monitoring product lines to hospitals worldwide through its direct sales organization in the United States and select European countries as well as an international network of distribution partners.  

IRRAS maintains its headquarters in Stockholm, Sweden, with corporate offices in Munich, Germany, and San Diego, California, USA. For more information, please visit www.irras.com. 

IRRAS is listed on Nasdaq Stockholm (ticker: IRRAS). 

For more information, please contact: 

USA
Will Martin
President and CEO

ir@irras.com 

Europe
Sten Gustafsson
Director, Investor Relations
sten.gustafsson@irras.com
+46 102 11 5172 

 

The information was released for public disclosure, through the agency of the contact person above, on September 29, 2021 at 08:30 (CET). 

IRRAS AB publishes Interim Report for the period, January to June 2021

“Q2 2021 marks the fourth consecutive quarter of growth for IRRAS despite the challenges of the COVID-19 pandemic, and the company is positioned to continue this positive growth trajectory."

“This is an exciting time for IRRAS as our forward progress accelerates. A record number of patients were treated with our products during Q2, and published clinical data and surgeon feedback both support our company’s positive impact on critically ill patients.”

Will Martin, President and CEO of IRRAS

Second Quarter, April – June 2021, Results

  • Net revenue amounted to SEK 5.1 million (1.2)
  • Operating loss (EBIT) amounted to SEK -26.7 million (-31.2)
  • Loss after tax amounted to SEK -27.1 million (-32.5)
  • Earnings per share before and after dilution amounted to SEK -0.40 (-0.55)

Period, January – June 2021, Results

  • Net revenue amounted to SEK 9.1 million (2.8)
  • Operating loss (EBIT) amounted to SEK -66.0 million (-66.5)
  • Loss after tax amounted to SEK -66.9 million (-66.9)
  • Earnings per share before and after dilution amounted to SEK -0.99 (-1.52)

Important events during the quarter

Strengthened Balance Sheet

  • A directed share issue in June generated proceeds of SEK 66 million before fees.
  • The company received forgiveness for the 832,055 USD (6.9M SEK) loan received as part of the US COVID-19 Paycheck Protection Program (PPP).

Key Quality System Certifications Received

  • IRRAS transitioned its notified body partnership for global regulatory and quality system oversight to global leader, DEKRA.
  • IRRAS received quality system certification under the EU Medical Device Regulation (MDR) 2017/745 and the Medical Device Single Audit Program (MDSAP), which allows the company to seek regulatory approval in key markets, such as Australia and Brazil.

Publication of case report

  • Buffalo General Medical Center published a case report that documented clinical superiority of the IRRAflow system versus traditional passive drainage systems.

Management Transition Announced

  • IRRAS announced that Kleanthis G. Xanthopoulos, Ph.D. would step down as CEO and remain on company’s Board of Directors.
  • CFO Sabina Berlin departed IRRAS, and Griffen Stapp, the company’s Controller, assumed the role of Interim CFO.

Important events after the end of the quarter

New CEO Appointed

  • Will Martin, the company’s President and Chief Commercial Officer, assumed the role of President and CEO.

Loan Agreement with European Investment Bank (EIB) Announced

  • IRRAS signed a 10M EUR loan agreement that provides non-dilutive financing for IRRAS to accelerate product development and clinical data generation in the EU.

Quality System Certifications Expanded

  • After an on-site audit, IRRAS’ new in-house manufacturing facility was added to its ISO 13485:2016 certification, and the MDSAP certificate was extended for 3 years.

The report is available on the company’s website:  https://investors.irras.com/en/reports-presentations.

About IRRAS

IRRAS is a global medical care company focused on delivering innovative medical solutions to improve the lives of critically ill patients. IRRAS designs, develops, and commercializes neurocritical care products that transform patient outcomes and decrease the overall cost of care by addressing complications associated with current treatment methodologies. IRRAS markets and sells its comprehensive, innovative IRRAflow and Hummingbird ICP Monitoring product lines to hospitals worldwide through its direct sales organization in the United States and select European countries as well as an international network of distribution partners.  

IRRAS maintains its headquarters in Stockholm, Sweden, with corporate offices in Munich, Germany, and San Diego, California, USA. For more information, please visit www.irras.com

IRRAS AB (publ) is listed on Nasdaq Stockholm (ticker: IRRAS).

For more information, please contact:

USA
Will Martin
President and CEO
ir@irras.com

Europe
Sten Gustafsson
Director, Investor Relations
sten.gustafsson@irras.com
+46 102 11 5172

This information is information that IRRAS is obliged to disclose pursuant to the EU market Abuse Regulation and the Swedish Securities Market Act. The information was released for public disclosure, through the agency of the contact person above, on August 26, 2021 at 08:00 (CET).

 IRRAS AB (publ) interim report for January to June 2021

Q2 Report 2021 – invitation to conference call and audiocast

Stockholm, August 19, 2021 – On Thursday, August 26, at 09.00 CET, IRRAS will host a conference call and an online presentation of its Q2 2021 interim report (which will have been published earlier on August 26 at 08.00 CET). The presentation will be held in English.

The dial-in numbers for the conference call are:

Sweden: +46 8 50 55 83 54
Rest of the world: +44 33 33 00 92 73

The presentation will be webcast and can be accessed from the following web address:
https://tv.streamfabriken.com/irras-q2-2021

Speakers: President and CEO Will Martin, Interim CFO Griffen Stapp, and Head of Investor Relations Sten Gustafsson

 

About IRRAS

IRRAS is a global medical care company focused on delivering innovative medical solutions to improve the lives of critically ill patients. IRRAS designs, develops, and commercializes neurocritical care products that transform patient outcomes and decrease the overall cost of care by addressing complications associated with current treatment methodologies. IRRAS markets and sells its comprehensive, innovative IRRAflow and Hummingbird ICP Monitoring product lines to hospitals worldwide through its direct sales organization in the United States and select European countries as well as an international network of distribution partners. 

IRRAS maintains its headquarters in Stockholm, Sweden, with corporate offices in Munich, Germany, and San Diego, California, USA. For more information, please visit www.irras.com.

IRRAS is listed on Nasdaq Stockholm (ticker: IRRAS).

 

For more information, please contact: 

Sten Gustafsson
Head of Investor Relations
sten.gustafsson@irras.com
+46 102 11 5172

 

The information was released for public disclosure, through the agency of the contact person above, on August 19, 2021 at 8:00 (CET).

IRRAS receives loan financing under European Guarantee Fund

Stockholm/Luxembourg, July 29, 2021 – IRRAS, a commercial-stage medical technology company with a comprehensive portfolio of innovative products for neurocritical care, has signed a loan financing agreement with the European Investment Bank (EIB), amounting to €10 million. The financing agreement with the EIB will provide non-dilutive financing for the company to accelerate product development and clinical data generation for its IRRAflow platform in the European Union. The financing from the EIB falls under the new venture debt programme of the European Guarantee Fund, set up in 2020 to assist European companies that have come under strain due to the COVID-19 pandemic.

Through the financing agreement, the company will be able to borrow up to €10 million in two loan tranches over the coming years based upon the achievement of agreed performance criteria. The initial loan amounts will be received during 2021 and will be allocated to fund next generation product development and clinical trial efforts based in the European Union. Utilising these funds for product development and clinical data generation will allow funds raised during the company’s recent direct share issue to be used to support continued acceleration of commercial launch activities. The specific terms and conditions of the financing agreement are not disclosed.

EIB Vice-President Thomas Östros stated: “IRRAS is a very innovative company whose growth plans were negatively impacted by the restrictions that were needed to fight COVID-19. Under the European Guarantee Fund we now have more possibilities to get financing to this type of company, which will help us support important home-grown European technologies in the wake of the pandemic.”

“The funding commitment by the EIB is the result of extensive due diligence over several months and serves as confirmation of IRRAS' ability to build a global leader in neurocritical care,” said Will Martin, President and Chief Executive Officer of IRRAS. “This investment enables us to collect additional clinical evidence to confirm the superiority of IRRAflow to traditional drainage, while also developing next generation systems that are tailored for targeted drug delivery and treatment in other clinical scenarios.”

Background information:

The European Investment Bank (EIB) is the long-term lending institution of the European Union owned by its Member States. It makes long-term finance available for sound investment in order to contribute towards EU policy goals. In 2020, the Bank made available in excess of €2 billion for Swedish projects. The EIB borrows money on the capital markets and lends it to projects that support EU objectives, with about 90% of all loans being granted within the European Union.

The European Guarantee Fund (EGF) was set up by the EIB Group with contributions from Sweden and other EU Member States to shield companies suffering from the COVID-19 crisis. Using nearly €25 billion in guarantees, the EGF enables the EIB and the EIF to quickly make loans, guarantees, asset-backed securities, equity and other financial instruments available to mostly small and medium-sized enterprises. The EGF is part of the European Union’s recovery package aiming to provide a total of €540 billion to boost those parts of the EU economy that have been hit the worst.

IRRAS is a global medical care company focused on innovative medical solutions to improve the lives of critically ill patients. IRRAS designs, develops, and commercialises neurocritical care products that transform patient outcomes and decrease the overall cost of care by addressing complications associated with current treatment methodologies. IRRAS markets and sells its comprehensive, innovative IRRAflow and Hummingbird ICP Monitoring product lines to hospitals worldwide through its direct sales organisation in the United States and select European countries as well as an international network of distribution partners.

IRRAS maintains its headquarters in Stockholm, Sweden, with corporate offices in Munich, Germany, and San Diego, California, USA. For more information, please visit www.irras.com.

IRRAS AB (publ) is listed on Nasdaq Stockholm (ticker: IRRAS).

IRRAflow®, the company’s lead commercial product, is used to drain blood and excess cerebrospinal or irrigation fluids and simultaneously monitor intracranial pressure in patients with haemorrhagic strokes and chronic subdural hematomas [1]. Both are serious conditions with high rates of mortality. IRRAflow® addresses complications that commonly arise from current treatment methods. At the same time, the company’s Hummingbird® ICP Monitoring family of products also offers an important diagnostic tool to monitor patients’ conditions after a traumatic brain injury has occurred. This tool is utilised to determine when intervention with a therapeutic tool, such as IRRAflow®, will be required and is more accurate and easier to use than other ICP monitoring systems.

[1] A subdural hematoma (SDH) is a type of bleeding in which a collection of blood—usually associated with a traumatic brain injury—gathers between the inner layer of the dura mater and the arachnoid mater of the meninges surrounding the brain.

 

For more information, please contact:

Sten Gustafsson
IR
sten.gustafsson@irras.com
+46 102 11 5172

Webiste: www.irras.com

 

Press contacts:

EIB: Tim Smit, t.smit@eib.org, tel.: +352 4379 89076, mobile: +352 691 286 423
Website:
www.eib.org/press – Press Office: +352 4379 21000 – press@eib.org

 

The information was released for public disclosure, through the agency of the contact person above, on 29 July 2021 at 18:00 (CET)

 IRRAS receives loan financing under European Guarantee Fund

IRRAS receives extension of its MDSAP certification and scope expansion of MDSAP & ISO 13485:2016 certifications

Stockholm, July 21, 2021 – IRRAS AB, a commercial-stage medical technology company with a comprehensive portfolio of innovative products for neurocritical care, announced today that it has successfully completed an in-person verification audit of its Quality Management System (QMS) by DEKRA, the company’s notified body.  Earlier this year, IRRAS announced that the company had received certification of its QMS under the Medical Device Single Audit Program (MDSAP).  As a result of this verification audit, the company’s MDSAP certification that covers both its IRRAflow and Hummingbird ICP Monitoring product lines will now be extended for two additional years and will remain valid until July 2024. 

This DEKRA audit also included a thorough inspection and validation of IRRAS’ new manufacturing facility, IRRAS South, Inc.  After this successful audit, IRRAS’ corporate ISO 13485:2016 certification will be expanded to also cover this facility, which has now been audited with no major findings by both the United States Food and Drug Administration (FDA) and DEKRA, IRRAS’ European regulatory representative.  IRRAS can now manufacture and globally ship medical devices from this facility based on these positive audit outcomes.

MDSAP is a stringent audit process that was established to enable medical device manufacturers to undergo one single audit of their QMS that covers the requirements of participating regulatory jurisdictions in Australia (TGA), Brazil (ANVISA), Canada (Health Canada), Japan(MHLW) and the United States (FDA).  This extended MDSAP certification will support IRRAS’ efforts to secure product regulatory clearance in these new markets.

“This recently completed audit is another strong confirmation of the meaningful progress made by our IRRAS team,” said Will Martin, President and CEO of IRRAS.  “Not only does the extension of our MDSAP certificate allow us to pursue meaningful regulatory approvals over the next three years, but it is an important milestone to receive ISO certification for IRRAS’ first in-house manufacturing facility.  This accomplishment validates our team’s collective commitment to quality and also secures necessary supply of IRRAflow capital equipment for our growing number of customers around the globe.”

About IRRAS
IRRAS is a global medical care company focused on delivering innovative medical solutions to improve the lives of critically ill patients. IRRAS designs, develops, and commercializes neurocritical care products that transform patient outcomes and decrease the overall cost of care by addressing complications associated with current treatment methodologies. IRRAS markets and sells its comprehensive, innovative IRRAflow and Hummingbird ICP Monitoring product lines to hospitals worldwide through its direct sales organization in the United States and select European countries as well as an international network of distribution partners.

IRRAS maintains its headquarters in Stockholm, Sweden, with corporate offices in Munich, Germany, and San Diego, California, USA. For more information, please visit www.irras.com.

IRRAS is listed on Nasdaq Stockholm (ticker: IRRAS).

 

For more information, please contact:

Sten Gustafsson
Investor Relations
sten.gustafsson@irras.com
+46 102 11 5172

The information was released for public disclosure, through the agency of the contact person above, on July 21, 2021 at 08:30 (CET).

 IRRAS receives extension of its MDSAP certification and scope expansion of MDSAP & ISO 13485:2016 certifications

Bulletin from Extraordinary General Meeting in IRRAS on July 15, 2021

At the Extraordinary General Meeting (the "EGM") held on July 15, 2021 it was resolved in accordance with the proposal by the Board of Directors to authorize the Board of Directors to resolve on entry into a credit facility with the European Investment Bank (EIB), where the interest rate or the amount to be repaid is raised should the result of the Company or dividend paid to shareholders of the Company, if any, increase.                            

The complete proposal by the Board of Directors is included in the notice to convene the EGM, which is available on IRRAS AB’s website www.irras.com.

About IRRAS

IRRAS is a global medical care company focused on innovative medical solutions to improve the lives of critically ill patients. IRRAS designs, develops, and commercializes neurocritical care products that transform patient outcomes and decrease the overall cost of care by addressing complications associated with current treatment methodologies. IRRAS markets and sells its comprehensive, innovative IRRAflow and Hummingbird ICP Monitoring product lines to hospitals worldwide through its direct sales organization in the United States and select European countries as well as an international network of distribution partners.

IRRAS maintains its headquarters in Stockholm, Sweden, with corporate offices in Munich, Germany, and San Diego, California, USA. For more information, please visit www.irras.com.

IRRAS AB (publ) is listed on Nasdaq Stockholm (ticker: IRRAS).

For more information, please contact:

USA

Will Martin
CEO
ir@irras.com

Europe

Sten Gustafsson
Director, Investor Relations
Email: sten.gustafsson@irras.com
Mobile: +46 721 44 7244

The information was released for public disclosure, through the agency of the contact persons above, on July 15, 2021 at 14:00 (CET).

 Bulletin from Extraordinary General Meeting in IRRAS on July 15, 2021

Will Martin Assumes Role as President and Chief Executive Officer of IRRAS

Stockholm, July 1, 2021 – IRRAS, a commercial-stage medical technology company with a comprehensive portfolio of innovative products for neurocritical care, today announced that Will Martin has formally assumed the role of President and Chief Executive Officer (CEO), which comes as part of a planned succession process first announced in April 2021. Kleanthis G. Xanthopoulos, Ph.D., will step down as CEO and will remain on the Company’s Board of Directors.

Will Martin joined IRRAS as Chief Commercial Officer in 2018. Prior to IRRAS, he most recently served as General Manager of the Peripheral Vascular devices business for Philips Healthcare, Vice President of Commercial Operations at AtheroMed, Inc. prior to its acquisition by Volcano Corporation, and held other key leadership roles at other life science companies. He holds a BA degree from The University of Notre Dame and an MBA from Johns Hopkins University and also served as a Lieutenant in the United States Navy.

“It has been a tremendous honor to serve as the CEO of IRRAS, and I am incredibly proud of the team and what we have accomplished together,” said Dr. Xanthopoulos.  “We have made meaningful progress to strengthen all elements of the company, and now, we are solely focused on commercial execution and acceleration. Will is the right leader to lead IRRAS into this next phase of growth.”

“I am incredibly excited and humbled to lead IRRAS during this important period,” said Martin. “We have now treated more than 200 patients with our IRRAflow system at more than 30 leading institutions, and we now have IRRAflow systems in place in 18 countries across 4 continents.  As COVID restrictions lessen globally, our products are helping more critically ill patients each day, and I look forward to positioning the company to best support hospitals and investors around the world.”

About IRRAS

IRRAS is a global medical care company focused on innovative medical solutions to improve the lives of critically ill patients. IRRAS designs, develops, and commercializes neurocritical care products that transform patient outcomes and decrease the overall cost of care by addressing complications associated with current treatment methodologies. IRRAS markets and sells its comprehensive, innovative IRRAflow and Hummingbird ICP Monitoring product lines to hospitals worldwide through its direct sales organization in the United States and select European countries as well as an international network of distribution partners.

IRRAS maintains its headquarters in Stockholm, Sweden, with corporate offices in Munich, Germany, and San Diego, California, USA. For more information, please visit www.irras.com

IRRAS AB (publ) is listed on Nasdaq Stockholm (ticker: IRRAS).

For more information, please contact:

Sten Gustafsson
IR
sten.gustafsson@irras.com
+46 102 11 5172

The information was released for public disclosure, through the agency of the contact person above, on July 1, 2021 at 08:30 (CET).

 Will Martin Assumes Role as President and Chief Executive Officer of IRRAS

Change in the total number of shares and votes in IRRAS AB

Stockholm, June 30, 2021 – IRRAS, a commercial-stage medical technology company with a comprehensive portfolio of innovative products for neurocritical care, today announced that as of 30 June 2021, the total number of shares and votes in IRRAS AB amounts to 79,481,340.

The number of shares and votes in IRRAS AB has increased as a result of the registration of 13,200,000 ordinary shares, which i accordance with previously announced information was issued in connection with the directed share issue carried out by the company on 10 June 2021.

About IRRAS

IRRAS is a global medical care company focused on innovative medical solutions to improve the lives of critically ill patients. IRRAS designs, develops, and commercializes neurocritical care products that transform patient outcomes and decrease the overall cost of care by addressing complications associated with current treatment methodologies. IRRAS markets and sells its comprehensive, innovative IRRAflow and Hummingbird ICP Monitoring product lines to hospitals worldwide through its direct sales organization in the United States and select European countries as well as an international network of distribution partners.

IRRAS maintains its headquarters in Stockholm, Sweden, with corporate offices in Munich, Germany, and San Diego, California, USA. For more information, please visit www.irras.com

IRRAS AB (publ) is listed on Nasdaq Stockholm (ticker: IRRAS).

For more information, please contact:

Sten Gustafsson
IR

sten.gustafsson@irras.com
+46 102 11 5172

This information is published in accordance with Chapter 4, Section 9 of the Swedish Financial Instruments Trading Act (SFS 1991:980). This press release was made public, through the agency of the person above on 30 June 2021, at 8.30 a.m. CEST.

 Change in the total number of shares and votes in IRRAS AB

NOTICE TO ATTEND THE EXTRAORDINARY GENERAL MEETING OF IRRAS AB (PUBL)

The shareholders of IRRAS AB (publ), org.nr 556872-7134 (”the Company”), are hereby invited to the Extraordinary General Meeting to be held on Thursday 15 July 2021. Due to the spread of the COVID-19, the Board of Directors has resolved that the Extraordinary General Meeting should be conducted without the psysical presence of shareholders, representatives or third parties and that the shareholders before the General Meeting should be able to exercise their voting right only by absentee ballot. 

Notice of Attendance 

A shareholder who would like to participate in the General Meeting shall: 

  1. be entered in the register of shareholders maintained by Euroclear Sweden AB by the record date Wednesday 7 July 2021; and 

  1. announce their intention to attend the General Meeting, by having submitted an absentee ballot in accordance with the instructions under the heading ”Absentee Ballot” below such that the Company has received the advance vote no later than Wednesday 14 July 2021. 

In order to be entitled to participate in the General Meeting, a shareholder who has registered their shares in the name of a nominee, in addition to announcing their intention to participate by submit its absentee ballot, must temporarily request that their shares be registered in their own name so the shareholder is entered into the register of shareholders by 7 July 2021.This registration may be temporary (so-called voting right registration) and is requested with the nominee in accordance with the nominee’s procedures and in advace as determined by the nominee. Voting right registrations completed no later than the 9 July 2021, will be considered when preparing the shareholder register. 

Absentee Ballot 

Shareholders may exercise their voting right at the General Meeting only by voting in advance, a so-called absentee ballot pursuant to section 22 of the Temporary Exemptions to Facilitate the Execution of General Meeting in Companies and Associations Act (2020:198). 

A special form must be used for the absentee ballot. This is available on the Company’s website www.irras.com. Terms and conditions for the absentee ballot are included in the form. The completed and signed form for the absentee ballot must be sent by mail to IRRAS AB (publ), Attn: CFO, P.O Box 160, 101 23 Stockholm or by e-mail to EGM@irras.com no later than 14 July 2021. The Shareholder may not add special instructions or conditions to the absentee ballot. If this occurs the vote (i.e. the absentee ballot in its entirety) will be invalid. If the shareholder submits an absentee ballot via proxy, the power of attorney must be attached to the form. The proxy form is available on the Company’s website, www.irras.com. If the shareholder is a legal person, the certificate of registration or other authorization document must be attached to the form.  

Matters to be dealt with at the Meeting and proposed agenda 

  1. Election of Chairman of the Meeting 

  1. Election of at least one person to certify the minutes  

  1. Preparation and approval of the voting list  

  1. Approval of the agenda  

  1. Establishment of whether the Meeting has been duly convened 

  1. Resolution in respect of authorization for the the Board of Directors to resolve on the issue of participating debentures  

Proposals  

Resolution in respect of authorization for the the Board of Directors to resolve on the issue of participating debentures (item 6) 

The Board of Directors proposes that the General Meeting authorizes the Board of Directors to, on one or more occasions, during the period up to the next Annual General Meeting, resolve on entry into a credit facility with the European Investment Bank (EIB), where the interest rate or the amount to be repaid is raised should the result of the Company or dividend paid to shareholders of the Company, if any, increase. 

The shareholders’ right to submit questions 

The Board of Directors and the CEO shall, if any shareholder so requests and the Board of Directors believes that it may be done without significantly harming the Company, provide information regarding circumstances that may affect the assessment of an item on the agenda. A request for such information shall be made in writing to the Company via mail to IRRAS AB (publ), Attn: CFO, Box 160, 101 23 Stockholm or by e-mail to EGM@irras.com, no later than 5 July 2021. The information shall be available on the Company’s website www.irras.com and on the Company’s head office as stated above no later than 10 July 2021.  

Other information 

As per the date of this notice, the total number of shares and votes in the Company amounts to 79,481,340. The Company holds no shares in the Company. For information about how your personal data will be processed, see  
https://www.euroclear.com/dam/ESw/Legal/Privacy-notice-bolagsstammor-engelska.pdf. 

Documents 

The proxy form and other documents in accordance with the Swedish Companies Act will be available at the Company’s office at the address set out above and will be sent free of charge to shareholders who so request and provide their postal address or e-mail address. The documents will also be available at the Company’s website, www.irras.com.  

_____ 

Stockholm June 2021 

The Board of Directors 

 

For more information, please contact:

Sten Gustafsson
IR
sten.gustafsson@irras.com
+46 102 11 5172

The information was released for public disclosure, through the agency of the contact person above, on June 23, 2021 at 17:00 (CET).


 

 NOTICE TO ATTEND THE EXTRAORDINARY GENERAL MEETING OF IRRAS AB (PUBL)

Irras Radio Irras Academy

At IRRAS, your privacy and the protection of your personal data are important to us. To ensure GDPR compliance, this website does not store or track any personal information, including Google Analytics or form submission data.
By using the website, you acknowledge and accept our policy.